Septerna (SEPN) Research & Development (2023 - 2026)
Septerna's quarterly Research & Development came in at $29.5 million in Q1 2026, up 53.26% year-on-year from $19.3 million in Q1 2025, and down 7.3% quarter-over-quarter from $31.9 million in Q4 2025.
Septerna has reported Research & Development for 4 years, with the latest figure at $29.5 million in Q1 2026.
- For the quarter ending Q1 2026, Research & Development rose 53.26% year-over-year to $29.5 million; the trailing twelve-month figure through Mar 2026 stood at $107.8 million (up 50.93% YoY), and the FY2025 full-year result was $97.6 million, up 49.35% from the prior year.
- Research & Development for Q1 2026 stood at $29.5 million, down from $31.9 million in the prior quarter.
- The five-year high for Research & Development was $31.9 million in Q4 2025, with the low at $9.3 million in Q3 2023.
- Average Research & Development over 4 years is $19.3 million, with a median of $19.3 million recorded in 2025.
- Year-over-year, Research & Development jumped 92.13% in 2024 and jumped 36.07% in 2025.
- Tracing SEPN's Research & Development over 4 years: stood at $10.3 million in 2023, then jumped by 87.07% to $19.3 million in 2024, then surged by 64.94% to $31.9 million in 2025, then retreated by 7.3% to $29.5 million in 2026.
- The last three Research & Development figures came in at $29.5 million (Q1 2026), $31.9 million (Q4 2025), and $24.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -2.30 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.54 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 364.87 Mn |
| 10 | Septerna | 1.34 Bn | 1.34 Bn | - | 29.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 29.54 Mn |
| Dec 31, 2025 | 31.86 Mn |
| Sep 30, 2025 | 24.26 Mn |
| Jun 30, 2025 | 22.19 Mn |
| Mar 31, 2025 | 19.27 Mn |
| Dec 31, 2024 | 19.32 Mn |
| Sep 30, 2024 | 17.83 Mn |
| Jun 30, 2024 | 15.04 Mn |
| Mar 31, 2024 | 13.15 Mn |
| Dec 31, 2023 | 10.33 Mn |
| Sep 30, 2023 | 9.28 Mn |